Ensuring top value of a product throughout the lifecycle process involves managing issues related to evaluating a potential product; Identifying the best people for a project, recognizing key value factors of a product, and managing the size, flow and duration of a project. This panel specifically addressed:
- How does your evaluation of a project differ in the big Pharma setting vs. a more entrepreneurial setting?
- What factors do you consider in determining whether their will be life after the patent on the active
- How have considerations changed in doing research (basic and developmental) in the last 10 years?
- What are some sources for evaluating the likelihood of success of a project?
Presenters included:
- Lisa Alexander, Corporate Patent Counsel, Novartis Institutes for Biomedical Research; Novartis Vaccines & Diagnostics
- Matt Bastardi, Vice President, Business Development & Licensing, Covidien
- James Burnes, Director, Health Care Investment Banking, Credit Suisse Securities LLC
- R. Brian McCaslin, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
Related Insights
November 7, 2025
Foley Viewpoints
Client Briefing: Texas Senate Bill 840 and Texas Senate Bill 2477 (89th Legislature, 2025 Session)
Texas S.B. 840 and S.B. 2477, effective September 1, 2025, significantly curtail how larger Texas cities regulate mixed-use and…
November 7, 2025
Energy Current
Uranium Designated as a US Critical Mineral in the 2025 USGS List: Three Things You Need to Know Now About this Landmark Action
On November 7, 2025 the U.S. Geological Survey (USGS), on behalf of the Secretary of the Interior, issued its Final 2025 List of Critical…
November 7, 2025
The Path & The Practice